{"id":"tp-59903","type":"article-newspaper","title":"Merck Ends Nemtabrutinib Development After Phase 3 Trial Review","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/59903","datePublished":"2026-11-17T22:13:06.000Z","dateModified":"2026-11-17T22:13:06.000Z","language":"en","abstract":"A data monitoring committee raised concerns that the drug’s potential benefits might not outweigh its risks.","section":"Business","references":[]}